GYN
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Antibody Drug Conjugates (ADCs) - Identifying New Therapeutic Approaches in Gynecologic Cancers
FEATURING
Susana Banerjee
- 80 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: dMMR Advanced/Recurrent Endometrial Cancer - Advances, Wins, and Challenges
FEATURING
Mansoor Raza Mirza
- 327 views
- September 20, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Advances in Cervical Cancer Management - Comprehensive Strategies for Recurrent or Metastatic Disease
FEATURING
Domenica Lorusso
- 201 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Advanced Ovarian Cancer - PRIMA Trial
FEATURING
Bradley J. Monk
- 442 views
- September 19, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagnosed Ovarian Cancer - ATHENA-COMBO Ph3 Trial
FEATURING
Bradley J. Monk
- 258 views
- September 19, 2024
- 1
ecancer
ESMO 2024 Insights: Novel ADC TORL-1-23 in Heavily-Pretreated Ovarian, Endometrial, and Testicular Cancers
FEATURING
Gottfried Konecny
- 41 views
- October 14, 2024
ecancer
ESMO 2024 Insights: PRIMA Trial - Newly Diagnosed Advanced Ovarian Cancer Treated With Niraparib for 1L Maintenance
FEATURING
Antonio González-Martín
- 137 views
- October 14, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Dose Optimization of Gotistobart + Pembro in Platinum-Resistant Ovarian Cancer - PRESERVE-004/GOG-3081 Study
FEATURING
Joyce Barlin
- 37 views
- October 16, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: HER2 Expression and Its Relationship to HRD Status and Biomarkers in Ovarian Cancer
FEATURING
Dahye Lee
- 56 views
- October 16, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Mirvetuximab Soravtansine-gynx (MIRV) in Platinum-Sensitive Ovarian Cancer With High FRα - PICCOLO Trial Results
FEATURING
Angeles Secord
- 123 views
- October 1, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Stereotactic RT Alone or Followed by Niraparib for OMD or OPD in Ovarian Cancer Following PARPi Therapy - SOPRANO Trial
FEATURING
Susana Banerjee
- 45 views
- October 7, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Risk Factors for Recurrence and Prognostic Subgroups in Stage I Uterine Leiomyosarcomas - Insights From the Daydream Study
FEATURING
Alejandro Gallego
- 31 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Induction Chemo Followed by CRT in Advanced Cervical Cancer - QoL Outcomes From GCIG INTERLACE
FEATURING
Gemma Eminowicz
- 69 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro or Placebo in Combination With Adjuvant Chemo +/- RT in Pts With Newly Diagnosed, High-Risk Endometrial Cancer From ENGOT-EN11/GOG-3053/KEYNOTE-B21
FEATURING
Brian Slomovitz
- 220 views
- September 26, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final OS From the ATALANTE/ENGOT-ov29 Trial Evaluating Atz vs. Placebo With Standard Cx + Bev in Ovarian Cancer Patients With Platinum-Sensitive Relapse
FEATURING
Jean-Emmanuel Kurtz
- 30 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Clinical and Molecular Predictors of Outcome in Patients With Tubo-Ovarian High-Grade Serous Carcinoma and Exceptional Survival
FEATURING
Tibor A. Zwimpfer
- 65 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: OS Results for Pembro + CRT for High-Risk Locally Advanced Cervical Cancer - ENGOT-cx11/GOG-3047/KEYNOTE-A18
FEATURING
Domenica Lorusso
- 173 views
- September 23, 2024
- 2